Loading...
•
Mar 31, 2020
Innoviva Q1 2020 Earnings Report
Reported financial results for Q1 2020.
Key Takeaways
Innoviva reported an increase in global net sales for RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, and TRELEGY® ELLIPTA® in the first quarter of 2020.
Global net sales of RELVAR®/BREO® ELLIPTA® increased 31% versus the first quarter of 2019.
U.S. net sales of RELVAR®/BREO® ELLIPTA® increased by 47% due to increased pricing discounts offset by a one-time significant positive prior period rebate adjustment and continued volume growth.
ANORO® ELLIPTA® global net sales increased 15% in the first quarter of 2020.
TRELEGY® ELLIPTA global net sales were $248.2 million.
Forward Guidance
The impact of the COVID-19 pandemic on the global sales of our three collaboration products is uncertain. First quarter sales levels may have benefited from unspecified levels of increased patient inventory stocking. The significant RELVAR®/BREO® ELLIPTA® positive prior period rebate adjustment that occurred during the first quarter is not likely to recur in future quarters.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...